Examkin

Question

Difficulty: HardNeoplastic Processes

A 58-year-old man presents to the clinic with a two-month history of fatigue, unintentional weight loss of 66 kg (1313 lbs), and intermittent bright red blood per rectum. Vital signs show a temperature of 37.1∘37.1^\circ C (98.8∘98.8^\circ F), blood pressure of 135/82135/82 mm Hg, heart rate of 8888/min, and respiratory rate of 1414/min. Physical examination reveals conjunctival pallor and mild left lower quadrant abdominal tenderness without guarding or rebound. A screening colonoscopy reveals a large, partially obstructing, friable mass in the sigmoid colon. Biopsy confirms moderately differentiated invasive adenocarcinoma. Subsequent staging computed tomography (CT) demonstrates multiple hepatic metastases. Molecular profiling of the tumor tissue reveals a missense mutation in the *KRAS* gene at codon 1212. The oncology team discusses initiating a systemic chemotherapy regimen. Based on the molecular profiling results, they explicitly decide to omit a specific biologic targeted therapy from the patient's treatment plan. Which of the following best describes the molecular basis for this tumor's primary resistance to the withheld biologic agent?

  1. Constitutive activation of a downstream GTP-binding protein independent of cell-surface receptor modulation.Answer
  2. B
    Accelerated clearance of the therapeutic agent due to induction of hepatic cytochrome P450 enzymes.
  3. C
    Upregulation of ATP-dependent transmembrane efflux pumps that prevent intracellular drug accumulation.
  4. D
    Conformational change in the extracellular domain of the targeted receptor preventing monoclonal antibody binding.
  5. E
    Constitutive activation of a downstream cytoplasmic serine/threonine kinase driving cellular proliferation.

Answer

Constitutive activation of a downstream GTP-binding protein independent of cell-surface receptor modulation.
The withheld biologic agents in this scenario are Epidermal Growth Factor Receptor (EGFR) inhibitors (e.g., cetuximab, panitumumab). EGFR normally stimulates cellular proliferation through the downstream RAS-RAF-MEK-ERK signaling pathway. KRAS is a membrane-anchored GTP-binding protein (GTPase) that functions as a critical switch in this cascade, alternating between an inactive GDP-bound state and an active GTP-bound state. Missense mutations in the KRAS gene, most commonly at codons 12 or 13, impair the protein's intrinsic ability to hydrolyze GTP. Consequently, the KRAS protein remains permanently locked in its active, GTP-bound conformation. Because this constitutive activation occurs downstream of EGFR, the signaling pathway continues to drive tumor growth even if a monoclonal antibody successfully binds and blocks the extracellular domain of EGFR. Therefore, EGFR inhibitors offer no clinical benefit and are absolutely contraindicated in KRAS-mutated colorectal cancer.

Step-by-Step Solution

1
Analyze the clinical presentation and biopsy results.
The patient has metastatic colorectal adenocarcinoma with a confirmed somatic KRAS mutation at codon 12.
Identifying the specific tumor histology and genetic profile is essential for determining appropriate targeted therapies.
2
Identify the biologic therapy that is contraindicated or withheld based on this specific genetic mutation.
Epidermal Growth Factor Receptor (EGFR) inhibitors, such as cetuximab and panitumumab, are withheld.
Current oncologic guidelines contraindicate the use of EGFR inhibitors in patients whose colorectal tumors harbor KRAS or NRAS mutations due to primary resistance.
3
Determine the molecular function of KRAS within the targeted signaling pathway.
KRAS is a membrane-bound GTP-binding protein (GTPase) that acts as an intracellular transducer downstream of the cell-surface EGFR.
Understanding the normal biochemical role of KRAS explains how somatic mutations alter cellular signaling.
4
Correlate the KRAS mutation with the mechanism of primary resistance to EGFR inhibitors.
The mutation causes KRAS to lose its intrinsic GTPase activity, locking it in a constitutively active (GTP-bound) state. Because KRAS sits downstream of EGFR, it continues to drive cellular proliferation even if the upstream EGFR is blocked by a monoclonal antibody.
This confirms that the resistance is due to constitutive activation of a downstream GTP-binding protein, making upstream receptor blockade futile.

Key Concept

Epidermal Growth Factor Receptor (EGFR) inhibitors are ineffective in colorectal cancers with KRAS mutations because the mutated downstream GTP-binding protein (KRAS) remains constitutively active regardless of upstream receptor blockade.
Rate this question

Topics

Neoplastic Processes

More questions from this topic